tiprankstipranks
Y-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
PremiumThe FlyY-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
2M ago
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
PremiumPress Releases
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
2M ago
Y-mAbs Therapeutics appoints Tagliaferri to board of directors
PremiumThe Fly
Y-mAbs Therapeutics appoints Tagliaferri to board of directors
2M ago
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PremiumPress ReleasesY-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
2M ago
YMAB Earnings this Week: How Will it Perform?
PremiumPre-Earnings
YMAB Earnings this Week: How Will it Perform?
2M ago
Y-mAbs Therapeutics price target raised to $21 from $11 at H.C. Wainwright
PremiumThe Fly
Y-mAbs Therapeutics price target raised to $21 from $11 at H.C. Wainwright
2M ago
Y-mAbs Therapeutics sees FY23 DANYELZA revenue  $80M- $85M, consensus $83.67M
PremiumThe FlyY-mAbs Therapeutics sees FY23 DANYELZA revenue $80M- $85M, consensus $83.67M
5M ago
Y-mAbs Therapeutics  reports Q3 EPS (18c), consensus (19c)
PremiumThe Fly
Y-mAbs Therapeutics reports Q3 EPS (18c), consensus (19c)
5M ago
YMAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
YMAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100